A phase I trial of intra-arterial delivery of SL 052 photodynamic therapy in patients with localised prostate cancer.
Phase of Trial: Phase I
Latest Information Update: 29 Nov 2011
At a glance
- Drugs SL 052 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Quest PharmaTech
- 29 Nov 2011 Status changed from planning to recruiting, according to a Quest PharmaTech media release.
- 11 May 2010 Planned number of patients changed from 12 to 18 according to Quest PharmaTech media release.
- 11 May 2010 According to a company media release, Quest PharmaTech has begun dosing of the first patient in this Phase I clinical trial of SL052 Photodynamic Therapy in prostate cancer patients.